Ipsen Press Releases | Latest News & Updates

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 239 Press Releases

Show

Sort

18 March 2026

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

12 March 2026

Ipsen appoints Michelle C. Werner as EVP, President of North America

09 March 2026

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

Notice of Epizyme, Inc. voluntary product recall for Tazemetostat Hydrobromide Tablets (Tazverik®)

27 February 2026

$Download Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma$

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

12 February 2026

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

FY 2025 – Results announcement (676.79 KB)

FY 2025 – Highlights (340.30 KB)

FY 2025 – Presentation (1.44 MB)

Your dedicated contacts

Sally Bain

Head of Global Media Relations

+1 857 320 0517

sally.bain@ipsen.com

Anne Liontas

France Media Relations

+33 7 67 34 72 96

anne.liontas.ext@ipsen.com

Press Releases

Explore more press releases

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

Ipsen appoints Michelle C. Werner as EVP, President of North America

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

Your dedicated contacts

Sally Bain

Anne Liontas

Stay updated

Press Releases

Explore more press releases

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

Ipsen appoints Michelle C. Werner as EVP, President of North America

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

1 related documents/links

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

3 related documents/links

Your dedicated contacts

Sally Bain

Anne Liontas

Stay updated